Parameter used in model | Value | Low range of sensitivity analyses | High range of sensitivity analyses | Distribution used in probabilistic analysis | Reference nos. |
---|---|---|---|---|---|
Utilities | |||||
Utility of post-ACS state in absence of heart failure | 0.91 | 0.56 | 1.00 | Beta | 24 |
Utility of post-ACS state in presence of heart failure | 0.55 | 0 | 1.00 | Beta | 24 |
Utility decrement associated with ACS | 0.18 for 1 mo | 0.10 | 0.26 | Beta | 25 |
Utility decrement associated with major bleed | 0.16 for 1 mo | 0 | 0.57 | Beta | 26 |
Utility decrements of minor adverse effects | 0.02 | 0 | 0.18 | Beta | 25, 26 |
Utility decrement associated with twice daily dosing for ticagrelor | 0.0001 | 0 | 0.04 | Beta | Assumption |
Costs, $ | |||||
Monthly cost of post-ACS state in presence of heart failure | 361.25 | 220 | 503 | Gamma | 27 |
Monthly cost of post-ACS state in absence of heart failure | 165.25 | 100 | 230 | Gamma | 27 |
Cost of ACS hospitalization | 9 774 | 0 | 32 404 | Gamma | 28 |
Hospitalization cost of major bleed | 10 805 | 0 | 38 255 | Gamma | 28 |
Physician billing during ACS hospitalization | 1 461 | 1 417 | 1 505 | Gamma | 29, assumption |
Physician billing during hospitalization for major bleed | 588 | 560 | 616 | Gamma | 29, assumption |
Monthly cost of clopidogrel | 20.09 | 15 | 25 | NA | 30 |
Monthly cost of prasugrel | 80.96 | 70 | 92 | NA | 30 |
Monthly cost of ticagrelor | 90.10 | 79 | 101 | NA | 30 |
Note: ACS = acute coronary syndrome, NA = not available.